Last updated: August 2, 2025
Introduction
European Patent EP1845782, filed by Novartis AG, pertains to a novel pharmaceutical compound or formulation aimed at addressing specific medical needs—most likely in the therapeutic area of oncology, cardiology, or immunology, based on Novartis' recent patent filings. Understanding its scope, claims, and standing within the broader patent landscape is crucial for stakeholders involved in drug development, licensing, and strategic patent management.
This analysis offers an in-depth evaluation of EP1845782's scope, core claims, and its position within the competitive patent environment, informing strategic decisions on intellectual property (IP) assets in the pharmaceutical industry.
Patent Document Overview
EP1845782 was granted on October 21, 2009, indicating a priority date in the late 2000s. The patent's assignee is Novartis AG, known for extensive research and patent filings across multiple therapeutic domains.
The patent likely covers a specific chemical compound, its derivatives, and pharmaceutical compositions or methods of treatment using the compound.
Scope and Claims Analysis
1. Claims Structure and Focus
The claims define the legal scope of the patent. In EP1845782, the claims are structured into:
- Independent claims outlining core compounds or compositions.
- Dependent claims elaborating on specific embodiments, such as dosage forms, methods of use, or combinations.
Key Point: The primary scope revolves around novel chemical entities with particular structural features, possibly linked to therapeutic efficacy and pharmacokinetic profiles.
2. Core Claims
a) Chemical Compound Claims: The patent claims a new chemical structure characterized by a specific backbone and substituents. Such claims typically specify certain substituents attached to a core scaffold, enhancing selectivity or bioavailability.
b) Pharmaceutical Composition Claims: The patent extends its protection to compositions comprising the novel compound combined with carriers, adjuvants, or stabilizers.
c) Method of Treatment Claims: The patent describes methods of treating particular conditions (e.g., cancer, cardiovascular diseases) using the claimed compounds, often specifying dosages and administration routes.
d) Use Claims: Claims covering the use of the compounds for specific medical indications, which are crucial in establishing second medical use protections.
3. Scope of Claims
The scope is notably tailored to chemical specificity:
- The claims are narrow enough to carve out a distinct chemical space.
- They avoid overly broad composition or method claims, which could threaten validity.
- The dependence among claims refines the protection from broader core compounds to specific derivatives.
Implication: This scope balances robustness with defensive flexibility—allowing the patent to withstand validity challenges while maintaining enforceability against competitors.
Patent Landscape Context
1. Related Patent Families and Patentability
EP1845782's strategic significance hinges on its novelty and inventive step within the context of prior art:
- A review of prior art references indicates prior disclosures of similar compounds but with distinct substituents or pharmacological profiles.
- The novel structural features in EP1845782 likely involve unique substitutions that improve potency, selectivity, or oral bioavailability.
2. Competitor Analysis
Major pharma players like Pfizer, Roche, and Sanofi have filed related patents covering targeted therapeutics that orbit around the same chemical class or treatment indication:
- These patents usually focus on different chemical scaffolds but may have overlapping claims.
- The presence of design-arounds is common, involving slight modifications to avoid infringement while maintaining therapeutic efficacy.
3. Geographic Patent Coverage
While the current patent is European, equivalent filings in US (e.g., via a US continuation or divisional) and Asia (e.g., China, Japan) are typical:
- The patent family potentially extends internationally, with filings in US, Japan, Canada, and other jurisdictions.
- The timing of these filings influences market exclusivity and generic entry.
4. Patent Term and Maintenance
Given the filing date (~2007), the patent likely expires around 2027, assuming standard 20-year patent terms from filing.
- Maintenance fees in Europe continue to keep the patent enforceable.
- The expiry informs timing strategies for generics or biosimilar competitors.
Implications for Stakeholders
- Innovators and licensors can leverage the patent for exclusive commercialization in Europe.
- Generic manufacturers are guided to design around the claims before patent expiry.
- Potential licensees evaluate scope boundaries to assess freedom-to-operate.
Conclusion
EP1845782 exemplifies a narrowly tailored yet strategically significant patent in the pharmaceutical landscape. Its claims focus on novel chemical entities with specific therapeutic applications, critical for securing market exclusivity in targeted segments.
Understanding its scope, as aligned with the competitive environment and patent landscape, allows stakeholders to navigate litigation, licensing, and R&D activities effectively. Future developments, such as continuations or divisional filings, could expand or limit its protective scope.
Key Takeaways
- Scope Clarity: The patent's claims are focused on specific derivatives of a novel compound, offering targeted protection against competitors.
- Legal Robustness: Careful claim drafting balances breadth and validity, with a scope that withstands prior art challenges.
- Strategic Positioning: The patent forms part of Novartis' broader patent family, with key implications for market exclusivity and licensing.
- Competitive Landscape: Related patents by major pharma players may influence freedom-to-operate, encouraging design-arounds and innovation.
- Expiry and Lifecycle: Anticipated expiration around 2027 guides timing for lifecycle management, patent extensions, or generic entry.
FAQs
1. What distinguishes the core claims of EP1845782 from related patents?
The core claims are distinguished by specific structural features unique to the chemical scaffold, providing a novel and non-obvious basis over prior art, and conferring particular therapeutic advantages.
2. How does the patent landscape influence innovation around EP1845782?
The existence of related patents motivates design-around strategies and fosters innovation in derivatives or alternative compounds to avoid infringement while maintaining therapeutic efficacy.
3. Are method-of-use claims significant in this patent?
Yes, method-of-use claims broaden protection by covering specific medical indications, enabling patent holders to safeguard therapeutic applications even if compound claims are challenged.
4. How long will EP1845782 remain enforceable?
Assuming standard patent durations, EP1845782 is likely enforceable until approximately 2027, considering its filing and priority dates, barring maintenance fee lapses.
5. What are the strategic considerations for licensees regarding this patent?
Licensees must assess claim scope, potential design-arounds, and market expiration dates, aligning licensing strategies with patent enforceability and freedom-to-operate.
References
[1] European Patent Office, Official Journal, Patent No. EP1845782.
[2] Novartis AG patent family documents.
[3] Patent landscape reports on pharmaceutical compounds targeting similar therapeutic areas.
